Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults
Approximately 44% of homeless adults are hepatitis C virus (HCV)-infected. [1] [2] [3] [4] [5] Historically, homeless and marginally housed (HMH) adults have faced barriers to HCV treatment. New, interferon-free therapies have excellent cure rates and improved tolerability, reducing barriers for treatment. 6 To our knowledge, no published studies have documented the treatment of HMH populations with these therapies. The Boston Health Care for the Homeless Program (BHCHP) began treating HMH adults with oral agents in 2014. Study inclusion criteria included the following: the individual (1) must be a BHCHP patient, (2) must be at least 18 years old, (3) must have chronic HCV infection (HCV antibody positive with detectable serum HCV RNA), (4) must be enrolled in HCV treatment with oral antiviral agents between February 2014 and August 2015, and (5) must have completed follow-up by December 31, 2015. The primary outcome was sustained virologic response for 12 weeks (SVR-12) (undetectable HCV RNA ≤15 IU/mL 12 weeks after treatment completion). We compared characteristics of the 2 subsets of respondents. Statistical analyses were conducted using STATA software (version 11; StataCorp Inc).
Results | From February 2014 and August 2015, 199 HMH individuals were considered for initiation of oral therapy; 64 were treated in the specified period and included in this analysis, 56 were treated outside the study period, and the rest remain untreated. Forty-nine of the 64 treated patients were male; their mean (SD) age was 55 years (7.7 years). Participant characteristics are shown in the Table, stratified by treatment outcome. All patients completed therapy without subspecialty referral.
Ninety-seven percent of patients (62 of 64) in this cohort achieved SVR-12. Treatment outcomes by treatment regimen are shown in the Figure. Only 13% reported more than 3 missed doses.
Two patients did not achieve SVR-12. Patient 1 was genotype 2 with cirrhosis, treatment naïve, HCV-monoinfected, and received only 12 weeks of sofosbuvir-ribavirin. The patient reported no missed doses of treatment, had an undetectable viral load at the end of treatment, but had a detectable viral load 12 weeks later. Patient 2 was genotype 1 with cirrhosis, treatment naïve, HCV-monoinfected, and was treated with ledipasvir-sofosbuvir for 12 weeks and missed 1 dose. The patient had a detectable viral load at end of treatment and resistance testing demonstrated H58P and L31V mutations.
Discussion | In this cohort of HCV-infected HMH adults, excellent responses to community-based treatment within a primary care program were observed with a SVR rate of 97% across genotypes and oral therapies. Viral resistance and treatment duration contributed to treatment failure in the 2 patients with treatment failure. These findings demonstrate that with a dedicated program for treating HCV in HMH adults in the primary care setting, it is possible to achieve outcomes similar to those of clinical trials and other cohorts despite significant additional barriers and competing priorities to health care faced by this population. 
